Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 415 results for cardiovascular disease

  1. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

    Medtech innovation briefing
    Published
    8 May 2019

  2. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Published
    20 December 2023
    View recommendations

    Sections for TA937

  3. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA235

  4. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    data. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  5. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

    Highly specialised technologies guidance
    Published
    6 July 2022
    View recommendations

    Sections for HST21

  6. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    knowledge and experience, the committee agreed that the risk of recurrent disease after successful parathyroid surgery is very low and...

    Research recommendation
    Published
    25 October 2019

  7. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    hyperthyroidism is persistent and appears to be caused by intrinsic thyroid disease. However, the committee noted that there is...

    Research recommendation
    Published
    10 February 2020

  8. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    risk. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  9. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M

    Diagnostics guidance
    Published
    21 November 2012
    View recommendations

    Sections for DG6

  10. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

    Research recommendation
    Published
    9 March 2022

  11. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

    Research recommendation
    Published
    9 March 2022

  12. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1017

  13. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  14. Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)

    Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.

    Interventional procedures guidance
    Published
    26 April 2006
    View recommendations

    Sections for IPG168

  15. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67)

    This guidance has been updated and replaced by NICE guideline CG181.

    Clinical guideline
    Published
    28 May 2008